DELIVERY ORDER
Active75F40126F19005
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$280K
obligated · signed 2 months ago
EO 14398 - POST-MARKETING RX DRUG ABUSE SURVEILLANCE DATA - DENVER HEALTH
Performance timeline
Start
Sep 30, 2026
End
Sep 29, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Sep 29, 2027
DENVER HEALTH AND HOSPITAL AUTHORITY
Contract 75F40126F19005
UEI
MMT4LGM4H9Z5
Parent Company
DENVER HEALTH AND HOSPITAL AUTHORITY
Capabilities & Certifications
Headquarters Location
Congressional District: 01
Current Obligation
$279,973
Base + Exercised Options
$279,973
Total Ceiling Value
$330,746
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
SPECIAL STUDIES/ANALYSIS- SCIENTIFIC DATA
Place of Performance
Congressional District: 01
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Contract Vehicle
75F40121D00033
IDCDepartment of Health and Human Services
Award type: MULTIPLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.